* ALIX *
2002 - Alsace
Strasbourg-Illkirch
www.alix-pharma.com Discovery, Drugs
(also Design, Protein)
Key words: NHR (Nuclear Hormone Receptors), Ligands, Protein crystallography, Cancer, Type II diabetes, Obesity, Early-stage
Mission: to discover, from early-stage, drugs based structure-based design using X-ray crystallography, with a main interest in nuclear hormone receptors, for cancers, type II diabetes, obesity and other metabolic diseases, also for neglected diseases such as schistosomiases, and to provide third parties with service activities in protein crystallization protein crystallography, and ligand screening using mass spectrometry
Clients: Research labs
info@alix-pharma.com
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS | | Spin-off |
Managing Dir.: Renaud (Jean-Paul) [founder, born 1960, Ph.D., ENSCP, ex-CNRS]
Sc.Dir.: Renaud (Jean-Paul)
Fin.Dir.:
BusDev:
Financers: privately owned (capital 2006 = 0.07 M€) | Turnover (M€) : 0.5 (2006)
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Multiple
Position : Preclin
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME | | 2008 .10 | Acquisition of Novalix (by merger), a contract research biotech company (60 employees) specialised in protein production and cristallography analysis | ACQ+ | [6 years] |
| 2002 .11 | Company founded by Jean-Paul Renaud, Jean Cavarelli, Dino Moras, Olivier Poch, Marc Ruff, Jean-Claude Thierry, Jean-Marie Wurtz, and Marat Yusupov, as a spin-off from the Department of Structural Biology and Genomics (DBGS) of the Institute of Genetics and Molecular and Cellular Biology (IGBMC) | ORGF | [0 year] | Actualisation / Updating: 31-Oct-2008 |
|
